FAQ: Lantern Pharma's LP-184 Phase 1a Clinical Trial Results and Future Plans

What is the main announcement from Lantern Pharma regarding LP-184?

Lantern Pharma announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints showing favorable safety, pharmacokinetic profile, and early signs of antitumor activity in patients with advanced relapsed or refractory solid tumors.

What were the key results from the Phase 1a trial of LP-184?

The trial demonstrated disease control in 48% of evaluable patients at therapeutic dose levels, with notable responses in DDR-deficient cancers including NSCLC, colon cancer, thymic carcinoma, and GIST. No dose-limiting toxicities were observed, and adverse events were predominantly mild.

How many patients participated in the Phase 1a trial and what types of cancers were studied?

The open-label study involved 63 patients with advanced relapsed or refractory solid tumors, including glioblastoma (GBM), and showed particular effectiveness in DDR-deficient cancers such as NSCLC, colon cancer, thymic carcinoma, and GIST.

What are Lantern Pharma’s next steps for LP-184 development?

Lantern plans to advance LP-184 into Phase 1b and Phase 2 studies targeting triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other DDR-deficient cancers using its RADR® AI platform for drug development.

What is Lantern Pharma’s RADR platform and how does it support drug development?

RADR® is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate oncology drug discovery and development, helping to solve real-world problems in cancer treatment.

What is the significance of these trial results for cancer patients?

The favorable safety profile and early antitumor activity suggest LP-184 could provide a new treatment option for patients with advanced solid tumors, particularly those with DDR-deficient cancers who have limited therapeutic alternatives.

Where can investors find more information about Lantern Pharma and its developments?

The latest news and updates relating to Lantern Pharma (NASDAQ: LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/y4dXg.

What types of cancers does Lantern Pharma’s pipeline target?

Lantern Pharma’s AI-driven pipeline includes therapies for multiple cancer indications spanning both solid tumors and blood cancers, with lead development programs in Phase 2 and multiple Phase 1 clinical trials, plus an antibody-drug conjugate (ADC) program.